APA (7th ed.) Citation

JC, Y., DH, L., JS, L., Y, F., F, d. M., E, I., . . . S, L. (2024). Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42(34), 4029. https://doi.org/10.1200/JCO.23.02747

Chicago Style (17th ed.) Citation

JC, Yang, et al. "Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 42, no. 34 (2024): 4029. https://doi.org/10.1200/JCO.23.02747.

MLA (9th ed.) Citation

JC, Yang, et al. "Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 42, no. 34, 2024, p. 4029, https://doi.org/10.1200/JCO.23.02747.